


VERSION OF CLAIMS WITH MARKINGS TO SHOW CHANGES MADE

1. ~~(twice amended)~~ A compound of formula (I) comprising ~~The~~ racemates, diastereoisomers and or optical isomers of a compound of formula (I):



wherein **B** is H, a C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C₁₋₆ alkyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C₁₋₆ alkyl; amido; or (lower alkyl)amide; or **B** is an acyl derivative of formula **R₄-C(O)-**; a carboxyl derivative of formula **R₄-O-C(O)-**; an amide derivative of formula **R₄-N(R₅)-C(O)-**; a thioamide derivative of formula **R₄-N(R₅)-C(S)-**; or a sulfonyl derivative of formula **R₄-SO₂** wherein

- R₄** is (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido, or (lower alkyl) amide;
(ii) C₃₋₇ cycloalkyl, C₃₋₇ cycloalkoxy, or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C₁₋₆ alkoxy)carbonyl, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido, or (lower alkyl) amide;
(iii) amino optionally mono- or di-substituted with C₁₋₆ alkyl; amido; or (lower alkyl)amide;
(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

R_5 is H or C_{1-6} alkyl; with the proviso that when R_4 -B is a carboxyl derivative, an amide derivative or a thioamide derivative, R_4 is not (ii)-a cycloalkoxy;

Y is H or C_{1-6} alkyl;

R^3 is C_{1-8} alkyl, C_{3-7} cycloalkyl, or C_{4-10} alkylcycloalkyl, all optionally substituted with hydroxy, C_{1-6} alkoxy, C_{1-6} thioalkyl, amido, (lower alkyl)amido, C_6 or C_{10} aryl, or C_{7-16} aralkyl;

R^2 is CH_2-R_{20} , $NH-R_{20}$, $O-R_{20}$ or $S-R_{20}$, wherein R_{20} is pyridinyl, quinolyl, (lower alkyl)-pyridinyl or (lower alkyl)-quinolyl, each optionally mono-, di- or tri-substituted with R_{21} ,

wherein each R_{21} is independently C_{1-6} alkyl; C_{1-6} alkoxy; lower thioalkyl; sulfonyl; NO_2 ; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C_{1-6} alkyl, C_6 or C_{10} aryl, C_{7-14} aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C_{1-6} alkyl, C_6 or C_{10} aryl, C_{7-14} aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C_6 or C_{10} aryl, C_{7-14} aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R_{22} ;

wherein R_{22} is C_{1-6} alkyl; C_{3-7} cycloalkyl; C_{1-6} alkoxy; amino optionally mono- or di-substituted with C_{1-6} alkyl; sulfonyl; (lower alkyl)sulfonyl; NO_2 ; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C_{1-6} alkyl;

R^1 is H; C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, all optionally substituted with halogen;

or a pharmaceutically acceptable salt or ester thereof;

wherein "Het" is defined as a five-membered saturated or unsaturated, including aromatic, heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, wherein said heterocycle is optionally fused to a benzene ring.

5. (amended) A compound of formula I according to claim 1, wherein B is a carboxyl derivative of formula $R_4-O-C(O)-$, wherein R_4 is

- (i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl, hydroxy, C_{1-6} alkoxy, amino optionally mono- or di-substituted with C_{1-6} alkyl, amido or (lower alkyl)amide;
- (ii) C_{3-7} cycloalkyl, C_{4-10} alkylcycloalkyl, all optionally substituted with carboxyl, (C_{1-6}

alkoxy)carbonyl, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide;

(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amido.

6. (amended) A compound of formula I according to claim 1, wherein **B** is an amide derivative of formula **R₄-N(R₅)-C(O)-** wherein **R₄** is

(i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

(iii) amino optionally mono- or di-substituted with C₁₋₃ alkyl;

(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide; and

R₅ is H or methyl.

7. (amended) A compound of formula I according to claim 1, wherein **B** is a thioamide derivative of formula **R₄-NH-C(S)-**; wherein **R₄** is

(i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl or C₁₋₆ alkoxy;

(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amino or amido.

11. (amended) A compound of formula I according to claim 5, wherein **B** is a carboxyl derivative of formula **R₄-O-C(O)-**, wherein **R₄** is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy or amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (ii) C₃₋₇ cycloalkyl, C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl, or
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amido, or amino optionally mono-substituted with C₁₋₆ alkyl.

12. (amended) A compound of formula I according to claim 6, wherein **B** is an amide derivative of formula **R₄-N(R₅)-C(O)-** wherein **R₄** is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (iii) amino optionally mono- or di-substituted with C₁₋₃ alkyl, or
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido optionally substituted with C₁₋₆ alkyl; or
- (v) Het optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido,

and **R₅** is H.


13. (amended) A compound of formula I according to claim 7, wherein **B** is a thioamide derivative of formula **R₄-NH-C(S)-**; wherein **R₄** is (i) C₁₋₁₀ alkyl; or (ii) C₃₋₇ cycloalkyl.

14. (amended) A compound of formula I according to claim 12, wherein **B** is an amide derivative of formula **R₄-NH-C(O)-** wherein **R₄** is


- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy

- amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido.


15. (amended) A compound of formula I according to claim 1, wherein **B** is



19. (amended) A compound of formula I according to claim 18, wherein **R**³ is the side chain of ~~tert~~-butylglycine (Tbg), Ile, Val, Chg or:




29. (twice amended) A compound of formula I according to claim 26, wherein **R**² is :



wherein **R**_{21A} is C₁₋₆ alkyl; C₁₋₆ alkoxy; lower thioalkyl; halo; amino optionally mono-substituted with C₁₋₆ alkyl; or C₆, C₁₀ aryl, C₇₋₁₆ aralkyl, or Het, said aryl, aralkyl or Het optionally substituted with **R**₂₂ wherein **R**₂₂ is C₁₋₆ alkyl, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl, or Het; and
R_{21B} is C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO₂, OH, halo, trifluoromethyl, or carboxyl.

30. (amended) A compound of formula I according to claim 29, wherein **R**_{21A} is C₆, C₁₀ aryl or Het, all optionally substituted with **R**₂₂ as defined in claim ~~30~~ 29.


32. (amended) A compound of formula I according to claim ~~29~~ 21, wherein **R**² is:



wherein **R**_{22A} is C₁₋₆ alkyl; C₁₋₆ alkoxy; or halo; and **R**_{21B} is C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO₂, OH, halo, trifluoromethyl, or carboxyl.

36. (twice amended) A compound of formula I according to claim 1, wherein **P**₁ is a cyclobutyl or cyclopropyl ring, both optionally substituted with **R**¹, wherein **R**¹ is H, C₁₋₃ alkyl, C₃₋₅ cycloalkyl, or C₂₋₄ alkenyl, all optionally substituted with halo.

37. (amended) A compound of formula I according to claim 36, wherein **P**₁ is: cyclopropyl



and **R**¹ is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.

45. (twice amended) A compound of formula I according to claim 1, wherein **B** is a C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C₁₋₆ alkyl; or

Het or (lower alkyl)-Het, all optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amido, or amino optionally substituted with C₁₋₆ alkyl, or

B is R₄-SO₂ wherein R₄ is preferably amido; (lower alkyl)amide; C₆ or C₁₀ aryl, C₇₋₁₄ aralkyl or Het, all optionally substituted with C₁₋₆ alkyl, or

B is an acyl derivative of formula R₄-C(O)- wherein R₄ is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, hydroxy or C₁₋₆ alkoxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl;
- (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl, or

B is a carboxyl derivative of formula R₄-O-C(O)-, wherein R₄ is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide;
- (ii) C₃₋₇ cycloalkyl, C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide;
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally mono- or di-substituted with C₁₋₆ alkyl, amido or (lower alkyl)amido, or

B is an amide derivative of formula R₄-N(R₅)-C(O)- wherein R₄ is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;

- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with C₁₋₆ alkyl;
 - (iii) amino optionally mono- or di-substituted with C₁₋₃ alkyl;
 - (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally substituted with C₁₋₆ alkyl; or
 - (v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl, amido or (lower alkyl)amide; and
- R₅ is H or methyl, or

B is thioamide derivative of formula R₄-NH-C(S)-; wherein R₄ is

- (i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl or C₁₋₆ alkoxy;
- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amino or amido;


Y is H or methyl;

R³ is C₁₋₈ alkyl, C₃₋₇ cycloalkyl, or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with hydroxy, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, acetamido, C₆ or C₁₀ aryl, or C₇₋₁₆ aralkyl;

R² is S-R₂₀ or O-R₂₀ wherein R₂₀ is pyridinyl, quinolyl, -CH₂-pyridinyl or -CH₂-quinolyl, all optionally mono-, di- or tri-substituted with R₂₁, wherein

R₂₁ is C₁₋₆ alkyl; C₁₋₆ alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted with C₁₋₆ alkyl, C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl, Het or (lower alkyl)-Het; NO₂; OH; halo; trifluoromethyl; carboxyl; C₆ or C₁₀ aryl, C₇₋₁₆ aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R₂₂, wherein


R₂₂ is C₁₋₆ alkyl; C₃₋₇ cycloalkyl; C₁₋₆ alkoxy; amino; mono- or di-(lower alkyl)amino; (lower alkyl)amide; sulfonylalkyl; NO₂; OH; halo; trifluoromethyl; carboxyl or Het; or




R² is

or R² is quinolinoxyl unsubstituted, mono- or di-substituted with R₂₁ as defined above; and

the **P1** segment is:



a cyclopropyl ring, both optionally substituted with R^1 , wherein R^1 is H, C_{1-3} alkyl, C_{3-5} cycloalkyl, or C_{2-4} alkenyl optionally substituted with halo, and said R^1 at carbon 2 is orientated *syn* to the carbonyl at position 1, represented by the radical:



or a pharmaceutically acceptable salt or ester thereof.

46. (twice amended) A compound of formula I according to claim 45, wherein **B** is a C_6 or C_{10} aryl optionally substituted with C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, hydroxy, hydroxyalkyl, halo, haloalkyl, nitro, cyano, cyanoalkyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C_{1-6} alkyl; or **B** is Het optionally substituted with C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, hydroxy, halo, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C_{1-6} alkyl; or

B is R_4-SO_2 wherein R_4 is C_6 or C_{10} aryl, a C_{7-14} aralkyl or Het all optionally substituted with C_{1-6} alkyl; amido, (lower alkyl)amide; **B** is an acyl derivative of formula $R_4-C(O)-$ wherein R_4 is

- (i) C_{1-10} alkyl optionally substituted with carboxyl, hydroxy or C_{1-6} alkoxy; or
- (ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, both optionally substituted with hydroxy, carboxyl, (C_{1-6} alkoxy)carbonyl; or
- (iv) C_6 or C_{10} aryl or C_{7-16} aralkyl, all optionally substituted with C_{1-6} alkyl, hydroxy; or
- (v) Het optionally substituted with C_{1-6} alkyl, hydroxy, amido or amino;

or **B** is a carboxyl derivative of formula $R_4-O-C(O)-$, wherein R_4 is

- (i) C_{1-10} alkyl optionally substituted with carboxyl, C_{1-6} alkanoyl, hydroxy, C_{1-6} alkoxy or

amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
(ii) C₃₋₇ cycloalkyl, C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl; or
(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with C₁₋₆ alkyl; or
(v) Het or (lower alkyl)-Het, both optionally substituted with C₁₋₆ alkyl, hydroxy, amido, or amino optionally mono-substituted with C₁₋₆ alkyl;

or **B** is an amide derivative of formula **R**₄-N(**R**₅)-C(O)- wherein **R**₄ is

(i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl; and **R**₅ is H or methyl; or


R₄ is (iii) amino optionally mono- or di-substituted with C₁₋₃ alkyl; or
(iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl, all optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido optionally substituted with C₁₋₆ alkyl; or
(v) Het optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido; or

B is a thioamide derivative of formula **R**₄-NH-C(S)-; wherein **R**₄ is:

(i) C₁₋₁₀ alkyl; or (ii) C₃₋₇ cycloalkyl; or


Y is H;

R³ is the side chain of ~~tert~~-butylglycine (**Tbg**), Ile, Val, Chg or:




R² is quinolinoxy unsubstituted, mono- or di-substituted with **R**₂₁ as defined above, or

R² is :



wherein **R**_{21A} is C₁₋₆ alkyl; C₁₋₆ alkoxy; C₆, C₁₀ aryl or Het; lower thioalkyl; halo; amino optionally mono-substituted with C₁₋₆ alkyl; or C₆, C₁₀ aryl, C₇₋₁₆ aralkyl or Het, optionally substituted with **R**₂₂ wherein **R**₂₂ is C₁₋₆ alkyl, C₁₋₆ alkoxy, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl, or Het;

P1 is: ~~a cyclopropyl ring wherein carbon 1 has the *R* configuration,~~



; and

R¹ is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl.


47. (amended) A compound of formula I according to claim 46, wherein

B is an amide derivative of formula **R**₄-NH-C(O)- wherein **R**₄ is


- i) C₁₋₁₀ alkyl optionally substituted with carboxyl, C₁₋₆ alkanoyl, hydroxy, C₁₋₆ alkoxy amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, all optionally substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C₁₋₆ alkyl;
- (iv) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl optionally substituted with C₁₋₆ alkyl, hydroxy, amino or amido;

R³ is the side chain of Tbg, Chg or Val;


R² is:




wherein **R_{22A}** is C₁₋₆ alkyl (such as methyl); C₁₋₆ alkoxy (such as methoxy); or halo (such as chloro); **R_{22B}** is C₁₋₆ alkyl, amino optionally mono-substituted with C₁₋₆ alkyl, amido, or (lower alkyl)amide; and **R_{21B}** is C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO₂, OH, halo, trifluoromethyl, or carboxyl;
and **P1** is:




50. (twice amended) A compound according to claim 45 represented by the formula:







wherein **B**, **R³**, **R²**, **R¹** are as defined below:

Table 2 Cpd #	B	R ³	R ²	R ¹ anti to carboxy
and 203	Boc	<i>t</i> -Bu		vinyl 1 <i>R</i> , 2 <i>R</i>

65. A compound according to claim 45 represented by the formula:



wherein B-N(Y)- , X , R_3R^3 , z and $\text{R}_{24\text{B}}$ and R^2 are as defined below:


Table 10 Cpd #	B-X-N(Y)-	R_3R^3	ZR^2	$\text{R}_{24\text{B}}$
1001	Ph-N(Me)-	<i>i</i> -Pr		H;
1002	Boc-NH-	<i>t</i> -Bu		OMe;
and 1003		<i>i</i> -Pr		—

REMARKS

Claims 1-26, 28-80 and 84-87 are pending.

I. Restriction Requirement

Applicants maintain their traversal of the restriction between the final product compounds of Groups I-VII and the intermediate compounds of Group XI (Claims 76-79). The Examiner maintains this restriction on the basis that newly cited Ishikawa et al. (JP 05-155827) teaches the use of the same intermediate compounds as endothelin antagonists. However, the compounds disclosed in Ishikawa are cis-2-aminocyclopropane-carboxylic acid derivatives of the formula I:



in which X is an amino or protected amino group and R is a protecting group. It is clear that these compounds are entirely different and structurally distinct from the intermediates of Group XI in which the amino and carboxyl group are bonded to the same ring carbon atom. Thus, it is clear that the compounds of Group XI do not correspond to the compounds of Ishikawa. Moreover, the compounds of Ishikawa are disclosed as intermediates to prepare endothelin antagonist peptides. Thus, there is clearly no reasonable expectation that the structurally different compounds of Group XI would be useful in any synthetic preparation technique disclosed in Ishikawa, and the Examiner has not identified any disclosure in Ishikawa supporting this theory. Accordingly, the Examiner is respectfully requested to reconsider and withdraw this part of the restriction requirement.

Applicants appreciate the Examiner's indication that the process claims will be rejoined in the examination at such time when the elected compounds are found to be allowable. On page 3, the Examiner does state that "such condensation reactions are well-known in the art by applicants' own admission (Specification at page 30, line 14)." For the record, the specification mentions only that the P1, P2 and P3 groups can be linked by "well known peptide coupling techniques." Thus, these techniques may be well-known in a general sense, but this is certainly no admission concerning the patentability of the specifically claimed processes all directed to preparing a peptide analog of formula (I) according to claim 1.

II. Rejection Under 35 USC 112, Second Paragraph

At pages 4-5 of the Office Action, various claims are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite, for the following reasons:

- (1) The use of the transitional word "comprising" in claim 1;
- (2) The definitions for the B substituent in various claims, the Examiner suggesting that the word "derivative" be inserted into the claims at various locations for the purpose of clarity;
- (3) Claim 30 refers back to itself for a definition;
- (4) Claim 32 lacks antecedent basis in claim 29 for "halo";
- (5) The definitions of P1 in claims 36, 37, 45 and 46, are inconsistent with claim 1;
- (6) The phrase "such as" in claim 47;
- (7) The identification of compounds by compound numbers in claims 49, 51, 53, 55, 57, 59, 61 and 63; and

(8) The use of the variables X and Y in claim 65 .

Applicants have amended the claims to specifically address items (1) through (6) and (8) raised by the Examiner. With respect to item (5), Applicants have added hydrogen (H) to the definition of R¹ for consistency with claim 1, this being identical to the previous language "optionally substituted with R¹."

With respect to item (7), Applicants traverse. Applicants submit that these claims do particularly point out and distinctly claim the subject matter of the invention since all the numbered compounds are specifically and clearly identified by structure in the preceding claim. Applicants are not aware of any regulation prohibiting the use of compound numbers in a claim when the compound numbers clearly identify the compound intended.

In view of the above, the Examiner is respectfully requested to reconsider and withdraw this rejection.

III. Provisos

Turning to the Examiner's note with respect to the provisos, the only proviso Applicants could identify in claim 1 is in the definition of B, following the definition of R₅:

"with the proviso that when R₄ is an amide (derivative) or a thioamide (derivative), R₄ is not (ii) cycloalkoxy;"


As is apparent from the reading of this proviso, there is a typographical mistake in that R₄ cannot be an amide or a thioamide in the claim. Indeed, this proviso should read:

"with the proviso that when **B** is a carboxyl derivative, an amide derivative or a


thioamide derivative, R_4 is not a cycloalkoxy.", and claim 1 has been so amended.

This proviso is needed to exclude compounds that are chemically unlikely or unstable. In this context, Applicants have added the carboxyl derivative to this proviso:


if **B** is a carboxyl of formula $R_4\text{-O-C(O)-}$ and if R_4 is C_{3-7} cycloalkoxy; then the resulting structure would be:



if **B** is an amide of formula $R_4\text{-N(R}_5\text{)-C(O)-}$ and if R_4 is C_{3-7} cycloalkoxy; then the resulting structure would be:



if **B** is a thioamide of formula $R_4\text{-N(R}_5\text{)-C(S)-}$ and if R_4 is C_{3-7} cycloalkoxy; then the resulting structure would be:



This proviso in claim 1 was not used up to eliminate compounds known to lack utility or

to bring the claims outside the scope of known prior art, as suggested by the Examiner but only to eliminate compounds that are likely to be chemically unstable.

IV. Claim Objections

Various claims are objected to for the following reasons:

- (1) Claim 1, the definition of Het embraces heterocycles that are non-elected under the terms of the Restriction Requirement. Likewise, claims 62 and 87 contain non-elected heterocycles.
- (2) Claims 15, 19 and 46 contain parentheticals for terms defined in the specification;
- (3) Claim 29 has a typo and claim 50 requires the deletion of "and".

Applicants have amended the claims to specifically address items (2) and (3).

With respect to item (1), although the Examiner is correct that these other 5-membered heterocycles are not embraced by Group II of the Restriction Requirement, Applicants submit that these other related compounds are most appropriately placed within elected Group II and would not constitute an undue examination burden on the Examiner. Applicants respectfully point out that the Examiner's Restriction Requirement set forth in the Office Action of 7/26/00 does not contain any group that would cover these claimed compounds, i.e., in which R₂₀ contains a pyridinyl or quinolyl group and Het is a 5-membered heterocycle other than those listed by the Examiner in Group II. Accordingly, given the structural relationship of the compounds - the same R₂₀ group containing a pyridinyl or quinolyl (which R₂₀ group likewise is not covered by any other Group of the restriction) and all having a 5-membered heterocycle in the

definition of Het – Applicants submit that all these related compounds should be examined together in Group II. No other Group of the Restriction Requirement contain compounds that are more closely related.

In addition, Applicant submit that it would not be an undue burden to examine all the claimed compounds given their structural relationship. As the Examiner is aware, it is the R₂₀ pyridine or quinoline group that will control the classification, not the 5-membered heteroring - i.e., all the claimed compounds will be classified in Class 546 as indicated for Group II.

For the above reasons, Applicants strongly believe that all the claimed subject matter should be examined together. If the Examiner maintains this requirement, the Examiner is respectfully requested to identify which Group of the Restriction Requirement would cover the compounds that the Examiner would have Applicants cancel from the claims and provide reasons as to why these compounds to be canceled are more appropriately examined in such other Group.

Applicants submit that the claim objection at the top of page 7 of the Office Action is now moot since all the claim rejections are believed to have been overcome.

Conclusion


In view of the above amendments and remarks, Applicants respectfully submit that this application is now in condition for allowance and earnestly request such action.

If any points remain at issue which can best be resolved by way of a telephonic or personal

U.S. Appln. No. 09/368,866
Amendment

interview, the Examiner is kindly requested to contact the undersigned attorney at the local telephone number listed below.

Respectfully submitted,


Philip I. Datlow
Reg. No. 41,482

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4542
Date: March 5, 2001

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner For Patents
Washington, DC 20231
on March 5, 2001.


Philip I. Datlow